NASDAQ:AZRX

AzurRx BioPharma Stock Forecast, Price & News

$0.97

+0.05 (+5.57 %)

(As of 01/21/2021 09:15 AM ET)

Add

Compare

Today's Range

$0.93

Now: $0.97▼

$1.07

50-Day Range

$0.74

MA: $0.83▼

$1.04

52-Week Range

$0.37

Now: $0.97▼

$1.30

Volume128,828 shs

Average Volume5.83 million shs

Market Capitalization$33.95 million

P/E RatioN/A

Dividend YieldN/A

Beta1.81

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company's therapeutic products are administered to patients as oral non-systemic biologics. Its lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.

MarketRank^™

Overall MarketRank^™

1.40 out of 5 stars

Medical Sector

544th out of 1,928 stocks

Pharmaceutical Preparations Industry

270th out of 774 stocks

3.4 Analyst's Opinion

Consensus Rating
AzurRx BioPharma has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, AzurRx BioPharma has a forecasted upside of 171.3% from its current price of $0.92.
Amount of Analyst Coverage
AzurRx BioPharma has only been the subject of 1 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
AzurRx BioPharma has received 215 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AzurRx BioPharma has received 145 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AzurRx BioPharma has received 59.72% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote “Outperform” if you believe AZRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AzurRx BioPharma does not currently pay a dividend.
Dividend Growth
AzurRx BioPharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AzurRx BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.30% of the stock of AzurRx BioPharma is held by insiders.
Percentage Held by Institutions
Only 5.14% of the stock of AzurRx BioPharma is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for AzurRx BioPharma are expected to grow in the coming year, from ($0.77) to ($0.36) per share.
Price to Book Value per Share Ratio
AzurRx BioPharma has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AZRX

Previous Symbol

CUSIPN/A

CIK1604191

Webwww.azurrx.com

Phone646-699-7855

Employees10

Debt

Debt-to-Equity RatioN/A

Current Ratio4.40

Quick Ratio4.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.17 per share

Price / Book5.72

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-15,180,000.00

Net MarginsN/A

Return on Equity-316.41%

Return on Assets-162.80%

Miscellaneous

Outstanding Shares34,900,000

Market Cap$33.95 million

Next Earnings Date2/15/2021 (Estimated)

OptionableNot Optionable

$0.97

+0.05 (+5.57 %)

(As of 01/21/2021 09:15 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

How has AzurRx BioPharma's stock price been impacted by COVID-19 (Coronavirus)?

AzurRx BioPharma's stock was trading at $0.6150 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AZRX shares have increased by 49.9% and is now trading at $0.9216.
View which stocks have been most impacted by COVID-19.

Is AzurRx BioPharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AzurRx BioPharma stock.
View analyst ratings for AzurRx BioPharma or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AzurRx BioPharma?

Wall Street analysts have given AzurRx BioPharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AzurRx BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as AzurRx BioPharma's CEO?

1,428 employees have rated AzurRx BioPharma CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among AzurRx BioPharma's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Monday, February 15th 2021.
View our earnings forecast for AzurRx BioPharma.

How were AzurRx BioPharma's earnings last quarter?

AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced its quarterly earnings results on Monday, November, 16th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.35.
View AzurRx BioPharma's earnings history.

What price target have analysts set for AZRX?

4 Wall Street analysts have issued 1-year price objectives for AzurRx BioPharma's stock. Their forecasts range from $2.00 to $3.00. On average, they expect AzurRx BioPharma's stock price to reach $2.50 in the next year. This suggests a possible upside of 171.3% from the stock's current price.
View analysts' price targets for AzurRx BioPharma or view Wall Street analyst' top-rated stocks.

Are investors shorting AzurRx BioPharma?

AzurRx BioPharma saw a drop in short interest in December. As of December 31st, there was short interest totaling 111,200 shares, a drop of 35.7% from the December 15th total of 172,900 shares. Based on an average daily volume of 160,100 shares, the days-to-cover ratio is currently 0.7 days.
View AzurRx BioPharma's Short Interest.

Who are some of AzurRx BioPharma's key competitors?

Some companies that are related to AzurRx BioPharma include Chembio Diagnostics (CEMI), Rezolute (RZLTD), Galectin Therapeutics (GALT), Rezolute (RZLT), Daré Bioscience (DARE), Oncolytics Biotech (ONCY), Rockwell Medical (RMTI), Vascular Biogenics (VBLT), Celyad Oncology (CYAD), Aprea Therapeutics (APRE), PhaseBio Pharmaceuticals (PHAS), Oramed Pharmaceuticals (ORMP), Cyclerion Therapeutics (CYCN), Actinium Pharmaceuticals (ATNM) and Xynomic Pharmaceuticals (XYNO).
View all of AZRX's competitors.

What other stocks do shareholders of AzurRx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the following people:

Mr. James R. Sapirstein R.Ph., M.B.A., CEO, Pres & Non-Independent Director (Age 59, Pay $443.61k)
Dr. James E. Pennington, Chief Medical Officer (Age 77, Pay $330k)
Mr. Martin Krusin M.B.A., Sr. VP of Corp. Devel.
Mr. Daniel H. Schneiderman, Chief Financial Officer (Age 42)

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an IPO on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $0.92.

How big of a company is AzurRx BioPharma?

AzurRx BioPharma has a market capitalization of $32.16 million. AzurRx BioPharma employs 10 workers across the globe.

What is AzurRx BioPharma's official website?

The official website for AzurRx BioPharma is www.azurrx.com.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here